Vivos Therapeutics (VVOS) Gains from Investment Securities (2019 - 2026)

Vivos Therapeutics (VVOS) has 8 years of Gains from Investment Securities data on file, last reported at $14000.0 in Q1 2026.

• Gains from Investment Securities for Q1 2026 came in at $14000.0, changed N/A year-over-year; the trailing twelve-month figure through Mar 2026 was $36000.0 (changed N/A YoY), and the FY2025 annual result was $90000.0, down 92.0% from the prior year.
• Gains from Investment Securities climbed to $14000.0 in Q1 2026 per VVOS's latest filing, from $11000.0 in the prior quarter.
• Over five years, Gains from Investment Securities peaked at $867000.0 in Q2 2023 and troughed at $600.0 in Q3 2022.
• A 5-year average of $151507.7 and a median of $86000.0 in 2023 frame the typical range for Gains from Investment Securities.
• The sharpest annual moves came in 2022 and 2023: Gains from Investment Securities plunged 99.98% in 2022, then surged 3900.0% in 2023.
• A 5-year view of Gains from Investment Securities shows it stood at $259000.0 in 2022, then slumped by 66.8% to $86000.0 in 2023, then tumbled by 94.19% to $5000.0 in 2024, then soared by 120.0% to $11000.0 in 2025, then advanced by 27.27% to $14000.0 in 2026.
• Business Quant data shows VVOS's Gains from Investment Securities at $14000.0 in Q1 2026, $11000.0 in Q4 2025, and $5000.0 in Q4 2024.